Barbara Gayle Duncan, Director at Aevi Genomic Medicine, Inc. (GNMX), bought 119,048 shares at $1.26 ($150K) on 2017-10-17, disclosed to the SEC on 2017-10-18.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $1.26 | 59,524 | $75K | 50.0% |
| 2 | $1.26 | 59,524 | $75K | 50.0% |
| Total | $1.26 avg | 119,048 | $150K | 100% |
| Filing → |
| JNCE | SELL | 2018-01-29 | $100K | — | Filing → |
| ICPT | SELL | 2016-10-05 | $24K | — | Filing → |
| ICPT | SELL | 2016-07-07 | $21K | — | Filing → |